AMP Commends Department of Health and Human Services on Decision to Lessen Regulatory Burden on Laboratory Professionals

Modernizing the CLIA Regulations is the Best Approach to Ensuring High Quality and Rapid Response Testing

Newswise — ROCKVILLE, Md. – August 21, 2020 - The Association for Molecular Pathology (AMP), the premier global, molecular diagnostics professional society, commends the decision by the U.S. Department of Health and Human Services (HHS) to rescind the requirement for premarket review of laboratory developed testing procedures (LDPs) by the Food and Drug Administration (FDA). LDPs are designed and performed by molecular diagnostic professionals whose laboratories are already regulated by the Centers for Medicaid & Medicare Services (CMS) through the Clinical Laboratory Improvement Amendments (CLIA). CLIA has a longstanding and successful history of promoting patient safety. This action by HHS reduces the duplicative regulatory burden placed on molecular diagnostic professionals wishing to use their expertise to provide high-quality, innovative LDPs, including those for SARS-CoV-2 in the COVID-19 Pandemic. 

“We are pleased with the decision of the U.S. Department of Health and Human Services to remove the overly burdensome requirement for molecular diagnostic professionals to submit their LDPs to FDA for pre-market review,” said Karen E. Weck, MD, President of the Association for Molecular Pathology. “This regulatory hurdle delayed the U.S. response in the early days of the coronavirus pandemic.  This illustrates the importance of qualified medical professionals being able to develop and quickly deploy essential new testing services, especially in response to a public health emergency.” 

AMP has long maintained that FDA oversight of LDPs slows innovation and compromises patient access to potentially lifesaving procedures. The regulatory process imposed by the FDA during the COVID-19 pandemic was duplicative with the CLIA regulations and impeded the ability of molecular diagnostic professionals, who practice at academic medical center, reference, and community health system laboratories across the country, to rapidly design, validate, and offer high-quality LDPs for use in patient care.   

The Association believes the best option for federal regulatory authority over LDPs is the modernization of the existing CLIA regulations, which are administered by the Centers for Medicare and Medicaid Services (CMS). In March, AMP supported US Senator Rand Paul’s (R-KY) introduction of new legislation that affirms molecular pathology professionals’ ability to continue advancing and offering LDPs for patient care. The Verified Innovative Testing in American Laboratories (VITAL) Act of 2020 clarifies the federal regulatory authority over LDPs and encourages the modernization of CLIA and administration by CMS. The legislation was designed to enhance transparency, preserve innovation, and ensure widespread patient access to essential medical services. 

“We believe this decision by HHS is a strong first step in clarifying regulatory authority and streamlining regulation of LDPs,” said Dr. Weck. “Our members welcome the opportunity to share our collective expertise and engage with key stakeholders to modernize the current CLIA oversight system in order to ensure high-quality testing without impeding innovation or compromising patient access.” 

To view the full-text version of the VITAL Act of 2020, visit To see AMP’s proposal to modernize the CLIA regulations and other resources regarding LDPs, visit here.



The Association for Molecular Pathology (AMP) was founded in 1995 to provide structure and leadership to the emerging field of molecular diagnostics. AMP's 2,500+ members practice various disciplines of molecular diagnostics, including bioinformatics, infectious diseases, inherited conditions, and oncology. Our members are pathologists, clinical laboratory directors, basic and translational scientists, technologists, and trainees that practice in a variety of settings, including academic and community medical centers, government, and industry. Through the efforts of its Board of Directors, Committees, Working Groups, and Members, AMP is the primary resource for expertise, education, and collaboration in one of the fastest growing fields in healthcare. AMP members influence policy and regulation on the national and international levels, ultimately serving to advance innovation in the field and protect patient access to high quality, appropriate testing. For more information, visit and follow AMP on Twitter: @AMPath

Filters close

Showing results

110 of 4147
Newswise: COVID-19 Peer Hub combats vaccine avoidance amid pandemic
Released: 27-Nov-2020 8:05 AM EST
COVID-19 Peer Hub combats vaccine avoidance amid pandemic
University of South Australia

UniSA researchers are evaluating a new vaccination education initiative – the COVID-19 Peer Hub – to help immunisation and public health professionals to tackle the emerging dangers of vaccine hesitancy amid the pandemic.

Newswise: Long-Term Impacts of COVID-19: Your Mental Health
Released: 25-Nov-2020 2:15 PM EST
Long-Term Impacts of COVID-19: Your Mental Health

The COVID-19 pandemic has shaped more than half a year of our lives, canceling plans, upending livelihoods and causing feelings of grief, stress and anxiety. And Cedars-Sinai mental health experts say the pandemic could be shaping our mental health well into the future.

Released: 25-Nov-2020 12:45 PM EST
SARS-CoV-2 mutations do not appear to increase transmissibility
University College London

None of the mutations currently documented in the SARS-CoV-2 virus appear to increase its transmissibility in humans, according to a study led by UCL researchers.

Newswise: COVID-19 vaccine candidate tested preclinically at UAB nears first clinical test in people
Released: 25-Nov-2020 11:05 AM EST
COVID-19 vaccine candidate tested preclinically at UAB nears first clinical test in people
University of Alabama at Birmingham

Maryland-based Altimmune Inc., a clinical stage biopharmaceutical company, has submitted an Investigational New Drug, or IND, application to the United States Food and Drug Administration to commence a Phase 1 clinical study of its single-dose intranasal COVID-19 vaccine candidate, AdCOVID.

Released: 25-Nov-2020 11:05 AM EST
BIDMC researchers reveal how genetic variations are linked to COVID-19 disease severity
Beth Israel Lahey Health

New research BIDMC-led sheds light on the genetic risk factors that make individuals more or less susceptible to severe COVID-19.

Newswise: blog-pandemic-scenario-planning-lg-feature2.jpg
Released: 25-Nov-2020 11:05 AM EST
Pandemic Ups Game on Scenario Planning in The Arts
Wallace Foundation

Researcher/Author of new toolkit and report seeks to help arts and culture organizations add scenario planning to their strategic toolbox

Released: 25-Nov-2020 10:30 AM EST
Young people's anxiety levels doubled during first COVID-19 lockdown, says study
University of Bristol

The number of young people with anxiety doubled from 13 per cent to 24 per cent, during the early stages of the COVID-19 pandemic and lockdown 1, according to new research from the University of Bristol.

Newswise: 249837_web.jpg
Released: 25-Nov-2020 10:20 AM EST
Tracking COVID-19 trends in hard-hit states
Louisiana State University

Currently, there are over 10 million confirmed cases and more than 240,000 casualties attributed to COVID-19 in the U.S.

Released: 25-Nov-2020 9:55 AM EST
More Health Systems Join National #MaskUp Campaign
Cleveland Clinic

Many more health systems are joining the national #MaskUp campaign encouraging Americans to stop the spread of COVID-19 by following safety guidelines. Over just a few days, another 19 health systems with hundreds of hospitals united with 100 health systems nationwide with hospitals numbering in the thousands. The public service campaign is critical to the health and well-being of all Americans. It is a plea from healthcare professionals everywhere: wear a mask and follow other precautions to save lives and help get our country back on its feet.

Newswise: delaterre_jpeg.jpg
Released: 25-Nov-2020 7:35 AM EST
Warwick scientists design model to predict cellular drug targets against Covid-19
University of Warwick

The covid-19 virus, like all viruses relies on their host for reproduction

Showing results

110 of 4147